|
1.
|
Sorlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
van de Vijver MJ, He YD, Van’t Veer LJ, et
al: A gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med. 347:1999–2009. 2002.
|
|
3.
|
van’t Veer LJ, Dai H, van de Vijver MJ, et
al: Gene expression profiling predicts clinical outcome of breast
cancer. Nature. 415:530–536. 2002.PubMed/NCBI
|
|
4.
|
Foekens JA, Atkins D, Zhang Y, et al:
Multicenter validation of a gene expression-based prognostic
signature in lymph node-negative primary breast cancer. J Clin
Oncol. 24:1665–1671. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Paik S, Shak S, Tang G, et al: A multigene
assay to predict recurrence of tamoxifen-treated, node-negative
breast cancer. N Engl J Med. 351:2817–2826. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Mamounas EP, Tang G, Fisher B, et al:
Association between the 21-gene recurrence score assay and risk of
locoregional recurrence in node-negative, estrogen
receptor-positive breast cancer: results from NSABP B-14 and NSABP
B-20. J Clin Oncol. 10:1677–1683. 2010. View Article : Google Scholar
|
|
7.
|
Habel LA, Shak S, Jacobs MK, et al: A
population-based study of tumor gene expression and risk of breast
cancer death among lymph node-negative patients. Breast Cancer Res.
8:R252006. View
Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Paik S, Tang G, Shak S, et al: Gene
expression and benefit of chemotherapy in women with node-negative,
estrogen receptor-positive breast cancer. J Clin Oncol.
24:3726–3734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Dowsett M, Nielsen TO, A’Hern R, et al
International Ki-67 in Breast Cancer Working Group: Assessment of
Ki67 in breast cancer: recommendations from the International Ki67
in Breast Cancer Working Group. J Natl Cancer Inst. 103:1656–1664.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wiedswang G, Borgen E, Karesen R, et al:
Isolated tumor cells in bone marrow three years after diagnosis in
disease-free breast cancer patients predict unfavorable clinical
outcome. Clin Cancer Res. 10:5342–5348. 2004.
|
|
11.
|
Braun S, Vogl FD, Naume B, et al: A pooled
analysis of bone marrow micrometastasis in breast cancer. N Engl J
Med. 353:793–802. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Xenidis N, Perraki M, Kafousi M, et al:
Predictive and prognostic value of peripheral blood cytokeratin-19
mRNA-positive cells detected by real-time polymerase chain reaction
in node-negative breast cancer patients. J Clin Oncol.
24:3756–3762. 2006. View Article : Google Scholar
|
|
13.
|
Janni W, Vogl FD, Wiedswang G, et al:
Persistence of disseminated tumor cells in the bone marrow of
breast cancer patients predicts increased risk for relapse - a
European pooled analysis. Clin Cancer Res. 17:2967–2976. 2011.
View Article : Google Scholar
|
|
14.
|
Rack B, Andergassen U, Janni W and
Neugebauer J: CTCs in primary breast cancer (I). Recent Results
Cancer Res. 195:179–185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Balic M, Lin H, Young L, et al: Most early
disseminated cancer cells detected in bone marrow of breast cancer
patients have a putative breast cancer stem cell phenotype. Clin
Cancer Res. 12:5615–5621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig
R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal
transition markers are frequently overexpressed in circulating
tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 11:R462009. View
Article : Google Scholar
|
|
17.
|
Stathopoulou A, Vlachonikolis I, Mavroudis
D, et al: Molecular detection of cytokeratin-19-positive cells in
the peripheral blood of patients with operable breast cancer:
evaluation of their prognostic significance. J Clin Oncol.
20:3404–3412. 2002. View Article : Google Scholar
|
|
18.
|
Raimondi C, Gradilone A, Naso G, et al:
Epithelial-mesenchymal transition and stemness features in
circulating tumor cells from breast cancer patients. Breast Cancer
Res Treat. 130:449–455. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Reuben JM, Lee BN, Gao H, et al: Primary
breast cancer patients with high risk clinicopathologic features
have high percentages of bone marrow epithelial cells with ALDH
activity and CD44+ CD24lo cancer stem cell phenotype.
Eur J Cancer. 47:1527–1536. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Kasimir-Bauer S, Hoffmann O, Wallwiener D,
Kimmig R and Fehm T: Expression of stem cell and
epithelial-mesenchymal transition markers in primary breast cancer
patients with circulating tumor cells. Breast Cancer Res.
14:R152012. View
Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Ellis IO, Schnitt SJ, Sastre-Garau X,
Bussolati G, Tavassoli FA, et al: Invasive breast carcinoma. World
Health Organization Classification of Tumours. Pathology and
Genetics of Tumours of the Breast and Female Genital Organs.
Tavassoli FA and Devilee P: IARC Press; Lyon: pp. 13–59. 2003
|
|
22.
|
Sobin LH and Wittekind C: International
Union Against Cancer. TNM Classification of Malignant Tumours. 6th
edition. Wiley-Liss; New York, NY: 2002
|
|
23.
|
Fehm T, Hoffmann O, Aktas B, Becker S,
Solomayer EF, Wallwiener D, Kimmig R and Kasimir-Bauer S: Detection
and characterization of circulating tumor cells in blood of primary
breast cancer patients by RT-PCR and comparison to status of bone
marrow disseminated cells. Breast Cancer Res. 11:R592009.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Janicke F, Pache L, Schmitt M, Ulm K,
Thomssen C, Prechtl A and Graeff H: Both the cytosols and detergent
extracts of breast cancer tissues are suited to evaluate the
prognostic impact of the urokinase-type plasminogen activator and
its inhibitor, plasminogen activator inhibitor type 1. Cancer Res.
54:2527–2530. 1994.
|
|
25.
|
Harbeck N, Thomssen C, Berger U, Ulm K,
Kates RE, Hofler H, Janicke F, Graeff H and Schmitt M: Invasion
marker PAI-1 remains a strong prognostic factor after long-term
follow-up both for primary breast cancer and following first
relapse. Breast Cancer Res Treat. 54:147–157. 1999. View Article : Google Scholar
|
|
26.
|
Fehm T, Braun S, Muller V, et al: A
concept for the standardized detection of disseminated tumor cells
in bone marrow of patients with primary breast cancer and its
clinical implementation. Cancer. 107:885–892. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Peto R, Boreham J, Clarke M, Davies C and
Beral V: UK and USA breast cancer deaths down 25% in year 2000 at
ages 20–69 years. Lancet. 355:18222000.PubMed/NCBI
|
|
28.
|
Early Breast Cancer Trialists’
Collaborative Group: Effects of chemotherapy and hormonal therapy
for early breast cancer on recurrence and 15-year survival: an
overview of the randomised trials. Lancet. 365:1687–1717.
2005.PubMed/NCBI
|
|
29.
|
Dowsett M and Dunbier AK: Emerging
biomarkers and new understanding of traditional markers in
personalized therapy for breast cancer. Clin Cancer Res.
14:8019–8026. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Dowsett M, Cuzick J, Wale C, et al:
Prediction of risk of distant recurrence using the 21-gene
recurrence score in node-negative and node-positive postmenopausal
patients with breast cancer treated with anastrozole or tamoxifen:
a TransATAC study. J Clin Oncol. 28:1829–1834. 2010. View Article : Google Scholar
|
|
31.
|
Albain KS, Barlow WE, Shak S, et al:
Breast Cancer Intergroup of North America: Prognostic and
predictive value of the 21-gene recurrence score assay in
postmenopausal women with node-positive,
oestrogen-receptor-positive breast cancer on chemotherapy: a
retrospective analysis of a randomised trial. Lancet Oncol.
11:55–65. 2010.
|
|
32.
|
Goldstein LJ, Gray R, Badve S, et al:
Prognostic utility of the 21-gene assay in hormone
receptor-positive operable breast cancer compared with classical
clinicopathologic features. J Clin Oncol. 26:4063–4071. 2008.
View Article : Google Scholar
|
|
33.
|
Markopoulos C: Overview of the use of
Oncotype DX® as an additional treatment decision tool in
early breast cancer. Expert Rev Anticancer Ther. 13:179–194.
2013.
|
|
34.
|
Tang G, Shak S, Paik S, et al: Comparison
of the prognostic and predictive utilities of the 21-gene
Recurrence Score assay and Adjuvant! for women with node-negative,
ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Breast Cancer Res Treat. 127:133–142. 2011.PubMed/NCBI
|
|
35.
|
Oakman C, Bessi S, Zafarana E, Galardi F,
Biganzoli L and Di Leo A: Recent advances in systemic therapy: new
diagnostics and biological predictors of outcome in early breast
cancer. Breast Cancer Res. 11:2052009. View
Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Brown RW, Allred CD, Clark GM, Osborne CK
and Hilsenbeck SG: Prognostic value of Ki-67 compared to S-phase
fraction in axillary node-negative breast cancer. Clin Cancer Res.
2:585–592. 1996.PubMed/NCBI
|
|
37.
|
Jung SY, Han W, Lee JW, et al: Ki-67
expression gives additional prognostic information on St. Gallen
2007 and Adjuvant! Online risk categories in early breast cancer.
Ann Surg Oncol. 16:1112–1121. 2009.PubMed/NCBI
|
|
38.
|
Weikel W, Beck T, Mitze M and Knapstein
PG: Immunohistochemical evaluation of growth fractions in human
breast cancers using monoclonal antibody Ki-67. Breast Cancer Res
Treat. 18:149–154. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Weikel W, Brumm C, Wilkens C, Beck T and
Knapstein PG: Growth fractions (Ki-67) in primary breast cancers,
with particular reference to node-negative tumors. Cancer Detect
Prev. 19:446–450. 1995.PubMed/NCBI
|
|
40.
|
Nicolini A, Carpi A and Tarro G:
Biomolecular markers of breast cancer. Front Biosci. 11:1818–1843.
2006. View Article : Google Scholar
|
|
41.
|
Perou CM, Sørlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2006. View
Article : Google Scholar
|
|
42.
|
Jones RL, Salter J, A’Hern R, et al: The
prognostic significance of Ki67 before and after neoadjuvant
chemotherapy in breast cancer. Breast Cancer Res Treat. 116:53–68.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Rakha EA, El-Sayed ME, Green AR, et al:
Prognostic markers in triple-negative breast cancer. Cancer.
109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Harbeck N, Schmitt M, Meisner C, et al:
Final 10-year analysis of prospective multicenter Chemo N0 trial
for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy
decision making in node-negative breast cancer. J Clin Oncol.
15S:5112009.
|
|
45.
|
Luporsi E, Andre F, Spyratos F, et al:
Ki-67: level of evidence and methodological considerations for its
role in the clinical management of breast cancer: analytical and
critical review. Breast Cancer Res Treat. 132:895–915. 2012.
View Article : Google Scholar
|
|
46.
|
Harbeck N, Alt U, Berger U, et al:
Prognostic impact of proteolytic factors (urokinase-type
plasminogen activator, plasminogen activator inhibitor 1, and
cathepsins B, D, and L) in primary breast cancer reflects effects
of adjuvant systemic therapy. Clin Cancer Res. 7:2757–2764.
2001.
|
|
47.
|
Janicke F, Prechtl A, Thomssen C, et al
German N0 Study Group: Randomized adjuvant chemotherapy trial in
high-risk, lymph node-negative breast cancer patients identified by
urokinase-type plasminogen activator and plasminogen activator
inhibitor type 1. J Natl Cancer Inst. 93:913–920. 2001. View Article : Google Scholar
|
|
48.
|
Cufer T, Borstnar S and Vrhovec I:
Prognostic and predictive value of the urokinase-type plasminogen
activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable
breast cancer. Int J Biol Markers. 18:106–115. 2003.PubMed/NCBI
|
|
49.
|
Look MP, van Putten WL, Duffy MJ, et al:
Pooled analysis of prognostic impact of urokinase-type plasminogen
activator and its inhibitor PAI-1 in 8,377 breast cancer patients.
J Natl Cancer Inst. 94:116–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
de Azambuja E, Cardoso F, de Castro G Jr,
et al: Ki-67 as prognostic marker in early breast cancer: a
meta-analysis of published studies involving 12,155 patients. Br J
Cancer. 96:1504–1513. 2007.PubMed/NCBI
|
|
51.
|
Schindlbeck C, Andergassen U, Hofmann S,
et al: Comparison of circulating tumor cells (CTC) in peripheral
blood and disseminated tumor cells in the bone marrow (DTC-BM) of
breast cancer patients. J Cancer Res Clin Oncol. 139:1055–1062.
2013. View Article : Google Scholar : PubMed/NCBI
|
